Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 12, 2006, Pages 1343-1349

  Wadehra, Navin ^a   Farag, Sherif ^b   Bolwell, Brian ^c   Elder, Patrick ^a   Penza, Sam ^a   Kalaycio, Matt ^c   Avalos, Belinda ^a   Pohlman, Brad ^c   Marcucci, Guido ^a   Sobecks, Ronald ^c   Lin, Thomas ^a   Andrèsen, Steven ^c   Copelan, Edward ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Autotransplant; Busulfan; Hodgkin's disease

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LIVER TOXICITY; LONG TERM CARE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; OVERALL SURVIVAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECOND CANCER; SOLID TUMOR; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 33845255237     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.08.039     Document Type: Article

References (57)

1. Canellos G.P., Anderson J.R., Propert K.J., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 (1992) 1478
2. Klimo P., and Connors J.M. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with MOPP/ABV hybrid program. Semin Hematol 25 (1994) 34
3. De Vita Jr. V.T., and Hubbard S.M. Hodgkin's disease. N Engl J Med 328 (1993) 560-565
4. Linch D.C., Winfield D., Goldstone A.H., et al. Dose identification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 341 (1993) 1051-1054
5. Schmitz N., Glass B., Dreger P., et al. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. Ann Hematol 66 (1993) 251-256
6. Lancet J.E., Rapoport A.P., Brasacchio R., et al. Auto-transplantation for relapsed or refractory Hodgkin's disease: long term follow-up and analysis of prognostic factors. Bone Marrow Transplant 22 (1998) 265-271
7. Lazarus H.M., Rowlings P.A., Zhang M.J., et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from Autologous Blood and Marrow Registry. J Clin Oncol 17 (1999) 534-545
8. Sweetenham J.W., Carella A.M., Taghipour G., et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. J Clin Oncol 17 (1999) 3101-3109
9. Yuen A.R., Rosenberg S.A., Hoppe R.T., Halpern J.D., and Horning S.J. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89 (1997) 814-822
10. Nademanee A., O'Donnel M.R., Snyder D.S., et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 85 (1995) 1381-1390
11. Horning S.J., Chao N.J., Negrin R.S., et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 89 (1997) 801-813
12. Gutierrez-Delgado F., Holmberg L., and Hooper H. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 32 (2003) 279-285
13. Kliss T.L., Panzarella T., Messner H.A., et al. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 31 (2003) 73-78
14. Avalos B.R., Klein J.L., Kapoor P.J., Tutschka P.J., Klein J.P., and Copeland E.A. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY. Bone Marrow Transplant 12 (1993) 133-138
15. Weaver C.H., Schwartzberg L., Rhinehart S., et al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 21 (1998) 383-389
16. Copelan E.A., Kapoor N., Gibbins B., and Tutschka P.J. Allogeneic marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 5 (1990) 47-50
17. Kroger N., Zabelina T., Sonnenberg S., et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 26 (2000) 711-716
18. Zander A.R., Berger C., Kroger N., et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res 3 (1997) 2671-2675
19. Kroger N., Hoffknecht M., Hanel M., et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant 21 (1998) 1171-1175
20. Copelan E.A., Penza S.L., Pohlman B., et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 25 (2000) 1243-1248
21. Hanel M., Kroger N., Sonnenberg S., et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 81 (2002) 96-102
22. Litzow M., Perez W., Klein J.P., et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 119 (2002) 1115-1124
23. Thomas E.D., and Storb R. Technique for human marrow grafting. Blood 36 (1970) 507-515
24. Bensinger W., Singer J., Appelbaum F., et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony stimulating factor. Blood 81 (1993) 3158-3163
25. Rowley S.D., Bensinger W., Goolet T.A., and Buckner C.D. The effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 83 (1994) 2731-2736
26. Lukes R.J., and Butler J.J. The pathology and nomenclature of Hodgkin's disease. Cancer Res 26 (1966) 1063-1081
27. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
28. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
29. Anderson J.E., Litzow M.R., Appelbaum F.R., et al. Allogeneic, syngeneic and autologous marrow transplantation for Hodgkin's disease: the 21 year Seattle experience. J Clin Oncol 11 (1993) 2342-2350
30. Deej H.J. Delayed complications after bone marrow transplantation. In: Forman S.J., Blum K.G., and Thomas E.D. (Eds). Bone Marrow Transplantation (1994), Scientific Publications, Boston, MA 538-544
31. Sureda A., Arranz R., Iriondo A., et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from Grupo Espanol de Linformas/Transplante Autologo de Medula Osease Spanish Cooperative Group. J Clin Oncol 19 (2001) 1395-1404
32. Jagannath S., Dicke K.A., Armitage J.O., et al. High-dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 104 (1986) 163-168
33. Lavoie J.C., Connors J.M., Phillips G.L., et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma: long-term outcome in the first 100 patients in Vancouver. Blood 106 (2005) 1473-1478
34. Chopra R., McMillan A.K., Linch D.C., et al. The place of high dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single center 8 year study of 155 patients. Blood 81 (1993) 1137-1145
35. Martin A., Fernandez-Jimenez M.C., Calallero M., et al. Long-term follow-up in patients treated with mini-BEAM as a salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 113 (2001) 171 2001
36. Jones R.J., Piantadosi S., Mann R., et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 8 (1990) 527-537
37. Schiffman K., Buckner C., Maziarz R., et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 3 (1997) 261-266
38. Farag S.S., Bolwell B.J., Elder P.J., et al. High-dose busulfan, cyclophosphamide, and etoposide do not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone Marrow Transplant 35 (2005) 653-661
39. Czyz J., Dziadziuszko R., Knopinska-Postuszuy W., et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 15 (2004) 1222-1230
40. Reece D.E., Barnett M.J., Shepherd J.D., et al. High-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16) with or without cisplatin and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86 (1995) 451-456
41. Crump M., Smith A.M., Brandwein J., et al. High dose etoposide and melphalan and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 11 (1993) 711
42. Kashyap A., Wingard J., Cagnoni P., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 8 (2002) 493-500
43. Crilley P., Topolsky D., Styler M., et al. Extramedullary toxicity of a conditioning regimen containing busulfan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogeneic bone marrow transplantation. Bone Marrow Transplant 15 (1995) 361-365
44. Siddiqui M.A., and Wellington K. Palifermin: in myelotoxic therapy-induced oral mucositis. Drugs 65 (2005) 2139-2146
45. Moskowitz C., Nimer S., Zelenetz A., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97 (2006) 616-623
46. Brice P., Bouabdallah R., Moreau P., et al. Prognostic factors for survival after high dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from French registry. Bone Marrow Transplant 20 (1997) 21-26
47. Sureda A., Constans M., Iriondo A., et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 16 (2005) 625-633
48. Copelan E.A., and Deeg H.J. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 80 (1992) 1658
49. Friedberg J.W., Neuberg D., Stone R.M., et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 17 (1999) 3128-3135
50. Anderson J.E., Gooley T.A., Schoch G., et al. Stem cell transplantation for secondary acute myeloid leukemia: an evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 89 (1997) 2578-2585
51. Metayer C., Curtis R.E., Vose J., et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 5 (2003) 2015-2023
52. Bolwell B., Kalaycio M., Sobecks R., et al. Secondary malignancy after autologous stem cell transplantation (ABMT) for non-Hodgkin's lymphoma and Hodgkin's disease using a busulfan containing preparative regimen. Blood 100 11 (2002) 418a
53. Curtis R., Rowlings P., Deeg H., et al. Solid cancers after bone marrow transplantation. N Engl J Med 336 (1997) 897-904
54. Miller J.S., Arthur D.C., Litz C.E., Neglia J.P., Miller W.J., and Weisdorf D.J. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 83 (1994) 3780-3786
55. Stone R.M., Neuberg D., Soiffer R., et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12 (1994) 2535-2542
56. Darrington D.L., Vose J.M., Anderson J.R., et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12 (1994) 2527-2534
57. Andre M., Henry-Amar M., Blaise D., et al. Treatment-related deaths and secondary cancer risk after autologous stem cell transplantation for Hodgkin's disease. Blood 92 (1998) 1933-1940